Philippe Rochigneux

@prochigneux

Medical Oncologist (Marseille, France).

Vrijeme pridruživanja: lipanj 2009.

Tweetovi

Blokirali ste korisnika/cu @prochigneux

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @prochigneux

  1. Poništi
  2. proslijedio/la je Tweet
    23. sij

    KRAS mutations in ctDNA correlated with recurrence free & overall survival in - while the separation of curves is not as impressive as , this is an opportunity to introduce novel treatments in the MRD setting.

    Poništi
  3. proslijedio/la je Tweet
    13. sij

    From 100 million patient visits, 155,000 doctors, > 400 health systems: Doctors spend > 16 minutes w/ electronic health record per encounter (which is more than time spent w/ the patient, much w/ EHR) From 's

    Prikaži ovu nit
    Poništi
  4. proslijedio/la je Tweet
    14. sij

    Larotrectinib shows impressive clinical efficacy in NTRK fusion positive NSCLC! Highlights from our poster presented at shown here. NTRK fusions should be included in molecular screening panels - must not miss!

    Poništi
  5. proslijedio/la je Tweet

    Dissecting the mechanisms of immune checkpoint therapy

    Poništi
  6. proslijedio/la je Tweet
    10. sij

    | Evidencia actual y desafíos futuros que abordan la eliminación del paradigma de la cirugía de después de la terapia sistémica neoadyuvante |Artículo completo🔎

    Poništi
  7. proslijedio/la je Tweet
    9. sij

    An important advance for immunotherapy Tom, given the major morbidity associated with Cystectomy- particularly in older patients.

    Poništi
  8. proslijedio/la je Tweet

    : The death rate declined by 29% from 1991-2017, including a 2.2% drop from 2016-2017. The steady 26-year decline is driven by long-term drops in death rates for the four major cancers- lung, colorectal, breast, & prostate.

    Poništi
  9. proslijedio/la je Tweet
    17. pro 2019.

    DS8201 is transforming BC: 60% ORR, 16 month PFS in refractory her2+++. ph III ongoing. next: .combo (parp inh to synergise with dxd , IO because lympho spared of chemo) .early stage to improve dfs AND QOL .her2-low .on treat biopsies for MOA (Daisy trial🇫🇷) (COI:res grant)

    Prikaži ovu nit
    Poništi
  10. proslijedio/la je Tweet
    18. pro 2019.

    TMT (= Turb and RTCT)in Bladder Cancer. Reviews by nature Ca Personalizedtreatment / biomarkers / QoL

    Poništi
  11. proslijedio/la je Tweet
    30. ruj 2019.

    Happening now!!!! New targeted tx for IDH1-mutated cholangiocarcinoma. (AKA ) met its primary endpoint of PFS advantage vs placebo. Congrats to , Milind Javle, and others. Excited that our global ph I effort materialized in only ~ 5 year

    Poništi
  12. 29. ruj 2019.
    Poništi
  13. 27. ruj 2019.

    Hope to see the combo soraf-nivo in the future. Hopefully not too toxic! Nivolumab Challenges Sorafenib as First-line Treatment | ESMO

    Poništi
  14. proslijedio/la je Tweet
    16. ruj 2019.

    A mass media promoting a large clinical trial, with two possible implications: a. incite citizen to participate in the trial, b. create awarness and educate. 👏🏼👏🏼👏🏼 and

    Poništi
  15. proslijedio/la je Tweet
    16. ruj 2019.

    Dr Arjun Saghal presenting a thoughtful discussion of NRG 0631- single fraction spine SBRT did not improve pain at 3 months vs palliative EBRT. Will be interesting to see LC anc retreat rates in the future.

    Poništi
  16. proslijedio/la je Tweet

    session: loved this study of patient costs and from showing that a rapid access clinic can help with patient financial burden. Specifically 8 Gy x1 was very helpful at reducing costs.

    Poništi
  17. proslijedio/la je Tweet
    8. ruj 2019.

    Larotrectinib in Lung NTRK. N= 12. ORR 75%. High CNS activity

    Prikaži ovu nit
    Poništi
  18. proslijedio/la je Tweet
    8. ruj 2019.

    Data fresh from 🇨🇳at on added clinical value added of for stage IV EGFR+ . In time for those ready to debate at EL9: can RT cure oligometaststic ? Keep it coming! See you there!

    , , i još njih 7
    Poništi
  19. proslijedio/la je Tweet
    9. ruj 2019.

    Update on hyperprogressive disease (HPD) - pts with NSCLC treated w single agent IO 1️⃣ OA14.06 Italy n=257 HPD 20.6% 2️⃣ P1.04.70 South Korea n=73 HPD 12% 3️⃣ P1.04.81 Latin-America n=110 HPD 19.8% 4️⃣ P2.04-77 Canada n=40 HPD 15% 5️⃣ P2.01-46 South Korea n=83 HPD 19.2%

    Poništi
  20. proslijedio/la je Tweet
    9. ruj 2019.

    Selpercatinib (formerly LOXO-292) in RET rearranged lung cancer. Results from LIBRETTO-001 Ph1/2 trial. KEY message: A phase 3 RCT is ongoing in this infrequent alteration. Needed? Ethical? Feasible? What do you think?

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·